US5264564A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Oligonucleotide analogs with novel linkages
Assignee: Ionis Pharmaceuticals Inc
•
Filing: 1990-07-30
•
Granted: 1993-11-23
•
Expires: 2010-07-30
Abstract
Abstract Oligonucleotide analogs wherein one or more phosphodiester linkages between adjacent nucleotides are replaced by an formacetal/ketal type linkage are resistant to nucleases and do not need to exhibit the diastereomerism characteristic of many other oligonucleotide analogs, and thus are capable of strong hybridization to target RNA or DNA. These oligonucleotide analogs are useful in therapies which modulate gene expression using "antisense" or other specifically binding oligomers.
Inventors
- 👤 Mark Matteucci
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 10:31
CPC Classifications
C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/06; C07H19/16; C07H21/00
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
47 words
A modified oligonucleotide wherein said modified oligonucleotide contains a nucleotide sequence useful in binding a target, wherein the modification comprises substitution for one or more phosphodiester linkages between individual nucleoside moieties a linkage of the formula --Y--CH 2 --Y--, wherein each Y is independently O or S.
Claim 2
Dependent Claim
47 words
A modified oligonucleotide wherein said modified oligonucleotide contains a nucleotide sequence useful in binding a target, wherein the modification comprises substitution for one or more phosphodiester linkages between individual nucleoside moieties a linkage of the formula --Y--CH 2 --Y--, wherein each Y is independently O or S.
Claim 3
Dependent Claim
12 words
The modified oligonucleotide of claim 1 which is a dimer or trimer.
Claim 4
Dependent Claim
16 words
The modified oligonucleotide of claim 1 wherein the --Y--CH 2 --Y-- linkage is --O--CH 2 --O--.
Claim 5
Dependent Claim
23 words
The modified oligonucleotide of claim 1 wherein the --Y--CH 2 --Y linkage is --O--CH 2 --S--; --S--CH 2 --O--; or --S--CH 2 --S--.
Claim 6
Dependent Claim
71 words
An oligomer of the formula ##STR9## wherein said oligomer contains a nucleotide sequence useful in binding a target, wherein each B is independently a purine or pyrimidine moiety, and wherein each Z is independently --P(O)O - or is --CH 2 --; and wherein n is 1-200, each m is 0 or 1, and wherein at least one Z is --CH 2 , and wherein each Y is independently O or S.
Claim 7
Dependent Claim
71 words
An oligomer of the formula ##STR9## wherein said oligomer contains a nucleotide sequence useful in binding a target, wherein each B is independently a purine or pyrimidine moiety, and wherein each Z is independently --P(O)O - or is --CH 2 --; and wherein n is 1-200, each m is 0 or 1, and wherein at least one Z is --CH 2 , and wherein each Y is independently O or S.
Claim 8
Dependent Claim
11 words
The oligomer of claim 5 which is a dimer or trimer.
References Cited (Backward Citations)
US4458066A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-11-22 | 1997-05-24 | 1997-11-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-11-22 | 2001-05-24 | 2001-11-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-11-22 | 2005-05-24 | 2005-11-23 | $7700.00 | Window Closed / Lapsed |